Beneficial treatment for early stage hepatitis c and hiv co-infection

https://www.contagionlive.com/view/beneficial-treatment-for-early-stage-hepatitis-c-and-hiv-co-infectionMarch 5, 2024 By Sophia Abene

Shortened treatments have shown promise in the early stages of hepatitis C (HCV), with a study on the 4-week glecaprevir/pibrentasvir (G/P) regimen presented at the Conference on Retroviruses and Opportunistic Infections (CROI), highlights a promising strategy for HCV elimination, particularly in HIV co-infected populations.

From November 2019 to January 2023, the study enrolled 45 participants predominantly male (98%), with a diverse racial background (51% White, 27% Black, 31% Hispanic/Latino), and a median age of 36 years (ranging from 22 to 65) from the US and Brazil. Of these, 27% reported a history of injecting drug use, 84% were diagnosed with their first HCV infection, and 51%were living with HIV, The median time from HCV diagnosis to study enrollment was 31 days (IQR: 15-49), with participants exhibiting a median baseline HCV RNA level of 5.3 log IU/mL (IQR: 3.3-6.0), predominantly genotype 1 (71%), and a median ALT level of 146 U/L (ranging from 22-3866).

The phase 2 study explored the efficacy and safety of a once-daily oral regimen of G/P 300 mg/120 mg for 4 weeks in adults with early-stage HCV. Eligibility for early-stage HCV included a significant new increase in ALT levels (either ≥5x the upper limit of normal (ULN) or >250 U/L if a normal ALT was documented in the year prior, or ≥10x ULN or >500 U/L if no prior ALT or an abnormal ALT was recorded) or detection of HCV RNA after a previously negative antibody test (indicating a first infection) or HCV RNA test (indicating reinfection) within the 24 weeks leading up to study participation.

TO CONTINUE READING: Beneficial Treatment for Early-Stage Hepatitis C and HIV Co-Infection https://www.contagionlive.com/view/beneficial-treatment-for-early-stage-hepatitis-c-and-hiv-co-infection